FOR: CARDIOCOMM SOLUTIONS, INC.
TSX VENTURE SYMBOL: EKG
CardioComm Solutions to begin immediate rollout of GEMS™ for Windows 7 remote ECG analysis, data management software to extensive base of current US health care providers and customers.
TORONTO, ONTARIO - CardioComm Solutions, Inc. (TSX VENTURE:EKG) (“CardioComm Solutions” or the “Company”), a global medical provider of electrocardiogram (“ECG”) acquisition and data management software solutions, is pleased to announce it will launch its new Global ECG Management System release (GEMS™ WIN), a Windows 7 compatible version of the Company’s GEMS™ software technology in June 2014.
The Company’s GEMS™ software is an industry standard clinic and service provider based software system used for remote ECG acquisition, analysis and data management for cardiac arrhythmia monitoring and implantable device follow up of patients by health care providers and services across the globe. Remote patient monitoring and follow up is a critical operational component of every cardiology practice internationally and gaining rapid adoption across the entire health care landscape.
CardioComm Solutions’ release of GEMS™ WIN is in response to the anticipated end of Microsoft support for Windows XP in April of 2014. The GEMS™ WIN software release will allow for functional operation of GEMS™ on the Windows 7 Operating System. Direct communications with existing GEMS™ customers and scheduling of GEMS™ WIN installations will begin in April. The Company confirms that GEMS™ WIN has been designed to maintain the exact functionality with familiar navigation and customizations that CardioComm Solutions customers previously had with their existing GEMS™ systems on the Windows XP Operating System.
“Moving to the new GEMS™ WIN release will ensure minimum downtime associated with the typical need for staff re-training, education and/ or application redevelopment of customer preferred reporting and operational capabilities. The aggressive marketing and promotions planned for the release of GEMS™ WIN for the Windows 7 OS compatible platform is anticipated to generate immediate sales revenue, market share growth and positive operating results for 2014,” said Simi Grosman, member of the Company’s board of directors.
“We are very pleased to offer our new, Windows 7 compatible version of GEMS™ to our existing customers,” commented Etienne Grima, CEO of CardioComm Solutions. “The GEMS™ WIN system will provide remote patient monitoring of cardiac arrhythmia and implantable device patients every day through health care providers and cardiac monitoring services. We will continue to enhance the GEMS™ technology platform to meet the current and future needs of the health care community as technology advances. This Windows 7 based release paves the way for the exciting introductions of future releases of our ECG interpretation and management technologies and service solutions in the coming year.”
“Our GEMS™ for Windows 7 release is a welcomed and exciting development that will solidify our technology provider relationship with hundreds of cardiology-based clinical providers and monitoring services across the United States and internationally,” commented Dan Pawlik, Vice President of Sales and Marketing for CardioComm Solutions. “For those customers who wish to continue operations with the existing features and benefits of the GEMS™-3 XP platform, this upgrade provides a nearly seamless transition. For new customers, we can now provide the benefits of GEMS™ and our future system enhancements without eminent Operating System obsolesce.”
About CardioComm Solutions
CardioComm Solutions’ patented and proprietary technology is used in products for recording, viewing, analyzing and storing electrocardiograms (ECGs) for diagnosis and management of cardiac patients. Products are sold worldwide through a combination of an external distribution network and a North American-based sales team. The Company has earned the ISO 13485 certification, is HPB approved, HIPAA compliant, and has received FDA market clearance for its software devices. CardioComm Solutions is headquartered in Toronto, Ontario, Canada, with offices in Victoria, B.C.
CardioComm Solutions' patented and proprietary
technology is used in products for recording,
viewing, analyzing and storing
electrocardiograms (ECGs) for diagnosis and
management of cardiac patients. Products
are sold worldwide through a combination of an
external distribution network and a North
American-based sales team. The Company has
earned the ISO 13485 certification, is HPB
approved, HIPAA compliant, and has received FDA
market clearance for its software devices.
CardioComm Solutions is headquartered in
Toronto, Canada, with offices in Victoria,
INFORMATION PLEASE CONTACT:
Etienne Grima, Chief Executive Officer
This release may contain certain forward-looking
statements and forward looking information with
respect to the financial condition, results of
operations and business of CardioComm Solutions
and certain of the plans and objectives of
CardioComm Solutions with respect to these
items. Such statements and information reflect
management's current beliefs and are based on
information currently available to management.
By their nature, forward-looking statements and
forward-looking information involve risk and
uncertainty because they relate to events and
depend on circumstances that will occur in the
future and there are many factors that could
cause actual results and developments to differ
materially from those expressed or implied by
these forward-looking statements and
In evaluating these statements, readers should:
specifically consider risks discussed under the
heading "Risk Factors" in the Company's Annual
Information Form, available at www.sedar.com;
not to place undue reliance on forward-looking
statements and forward-looking information; be
aware. the Company does not assume any
obligation to update the forward-looking
statements and forward-looking information
contained in this Annual Information Form other
than as required by applicable laws (including
without limitation Section 5.8(2) of National
Instrument 51-102 (Continuous Disclosure
Neither TSX Venture Exchange nor its Regulation
Services Provider (as that term is defined in
policies of the TSX Venture Exchange) accepts
responsibility for the adequacy or accuracy of